- Concurrent chemotherapy and radiation therapy (RT) remains the standard of care for nonsurgical treatment of stage III non–smallcell lung cancer (NSCLC) patients with good performance status.
- Although we should continue to explore radiation dose escalation/ acceleration in locally advanced NSCLC, administration of RT at doses of 60 Gy to 66 Gy with concurrent chemotherapy remains the standard regimen in the community setting.
- Both 3D conformal RT and intensity- modulated RT (IMRT) are acceptable for treatment of locally advanced NSCLC. Proton therapy may have the potential to further spare critical normal tissues, although more prospective studies are needed.
- Molecular marker–based targeted therapy might have the potential to improve the therapeutic ratio in locally advanced NSCLC, but more prospective studies are needed. At this time, there is no level 1 evidence to support adding targeted therapy with concurrent chemotherapy/RT.